Journal
SEMINARS IN DIALYSIS
Volume 34, Issue 6, Pages 416-422Publisher
WILEY
DOI: 10.1111/sdi.12959
Keywords
anticoagulation; citrate; continuous renal replacement therapy
Categories
Ask authors/readers for more resources
The choice of anticoagulant for CRRT should be based on patient characteristics, local expertise, and monitoring convenience. The KDIGO guidelines recommend using RCA instead of UFH in patients without increased risk of bleeding.
The most common anticoagulant options for continuous renal replacement therapy (CRRT) include unfractionated heparin (UFH), regional citrate anticoagulation (RCA), and no anticoagulation. Less common anticoagulation options include UFH with protamine reversal, low-molecular weight heparin (LMWH), thrombin antagonists, and platelet inhibiting agents. The choice of anticoagulant for CRRT should be determined by patient characteristics, local expertise, and ease of monitoring. The Kidney Disease Improving Global Outcomes (KDIGO) acute kidney injury guidelines recommend using RCA rather than UFH in patients who do not have contraindications to citrate and are with or without increased risk of bleeding. Monitoring should include evaluation of the anticoagulant effect, circuit life, filter efficacy, and complications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available